Literature DB >> 19945895

Desflurane-induced postconditioning of diabetic human right atrial myocardium in vitro.

S Lemoine1, C Durand, L Zhu, C Ivasceau, O Lepage, G Babatasi, M Massetti, J L Gérard, J L Hanouz.   

Abstract

AIM: We tested the hypothesis that brief exposure to desflurane at the time of reoxygenation might be able to protect against hypoxia-reoxygenation injury in human myocardium from diabetic (insulin-dependent, ID; and non-insulin-dependent, NID) patients and non-diabetic (ND) subjects.
METHODS: The force of contraction (34 degrees C, stimulation frequency 1Hz) in the right atrial trabeculae was recorded during 30min of hypoxia followed by 60min of reoxygenation. Desflurane (at 3, 6 and 9%) was administered during the first 5min of reoxygenation. The force of contraction at the end of the 60-min reoxygenation period (FoC(60)) was compared in the study groups (means+/-SD).
RESULTS: In the ND group, desflurane at 3, 6 and 9% (FoC(60): respectively 78+/-10%, 84+/-4% and 85+/-12% of baseline) enhanced the recovery of FoC(60) compared with the ND-controls (53+/-7% of baseline; P<0.05). In the ID group, desflurane at 3% (61+/-4%) did not modify the recovery of FoC(60) compared with the ID-controls (54+/-6%), whereas desflurane at 6 and 9% (75+/-11% and 81+/-8%, respectively) enhanced the recovery of FoC(60)vs the controls (P<0.05). In the NID group, desflurane at 3% (57+/-5%) also failed to modify the recovery of FoC(60) compared with the NID-controls (52+/-10%), while desflurane at 6 and 9% (80+/-10% and 79+/-7%, respectively) enhanced the recovery of FoC(60)vs the controls (P<0.05).
CONCLUSION: Desflurane in vitro was able to postcondition diabetic (both ID and NID) human myocardium at 6 and 9%, but not at 3%. Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945895     DOI: 10.1016/j.diabet.2009.06.006

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  5 in total

1.  In vitro Models of Ischemia-Reperfusion Injury.

Authors:  Timothy Chen; Gordana Vunjak-Novakovic
Journal:  Regen Eng Transl Med       Date:  2018-05-10

Review 2.  Anaesthetics as cardioprotectants: translatability and mechanism.

Authors:  C Kikuchi; S Dosenovic; M Bienengraeber
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

3.  Loss of Intralipid®- but not sevoflurane-mediated cardioprotection in early type-2 diabetic hearts of fructose-fed rats: importance of ROS signaling.

Authors:  Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Andreas Affolter; Manoj Gandhi; Martin Hersberger; Blair E Warren; Hélène Lemieux; Hany F Sobhi; Alexander S Clanachan; Michael Zaugg
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

Review 4.  Cardioprotection with halogenated gases: how does it occur?

Authors:  Jose Luis Guerrero-Orriach; Juan Jose Escalona Belmonte; Alicia Ramirez Fernandez; Marta Ramirez Aliaga; Manuel Rubio Navarro; Jose Cruz Mañas
Journal:  Drug Des Devel Ther       Date:  2017-03-16       Impact factor: 4.162

Review 5.  Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.

Authors:  Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick
Journal:  Cardiovasc Diabetol       Date:  2017-12-04       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.